J Am Coll Cardiol
October 2014
Objective: Return-to-play (RTP) decisions are a central component of the Team Physician's clinical work, yet there is little more than anecdotal reference to these in the literature. We recently published a 3-step model for return-to-play medical decision making and, in the current paper, undertook a systematic review of the literature to determine the level of evidence in support of this model.
Data Sources: PubMed, Web of Science, and CINAHL electronic databases.
A group of relatively uncommon but important genetic cardiovascular diseases (GCVDs) are associated with increased risk for sudden cardiac death during exercise, including hypertrophic cardiomyopathy, long-QT syndrome, Marfan syndrome, and arrhythmogenic right ventricular cardiomyopathy. These conditions, characterized by diverse phenotypic expression and genetic substrates, account for a substantial proportion of unexpected and usually arrhythmia-based fatal events during adolescence and young adulthood. Guidelines are in place governing eligibility and disqualification criteria for competitive athletes with these GCVDs (eg, Bethesda Conference No.
View Article and Find Full Text PDFIn brief An important medicolegal issue is how best to resolve disputes about an athlete's medical eligibility. Team physicians typically recommend against athletic participation when they feel that it will pose an unreasonable risk of injury to an athlete who has an abnormality. But such athletes may cite federal laws designed to protect the disabled and claim a right to participate.
View Article and Find Full Text PDF